Most important, the relatively cheap to synthesize CaSR NAMs appears to be the so far unique class of anti-AD therapeutics capable of concurrently targeting the multiple noxious effects triggered by pathological Aβs•CaSR signaling in human neurons, astrocytes, and the other brain cell types (Chiarini et al., 2010; Dal Prà et al., 2011; Armato et al., 2013; Dal Prà et al., 2014b; Dal Prà et al., 2015a; Chiarini et al., 2016). Here, DDX41 is linked to Alzheimer disease.